2014 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
Date Title
Dec 07, 2014Printer Friendly VersionTakeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
Dec 07, 2014Printer Friendly VersionSeattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Dec 06, 2014Printer Friendly VersionSeattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Dec 06, 2014Printer Friendly VersionTakeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
Dec 01, 2014Printer Friendly VersionTakeda’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis
Nov 06, 2014Printer Friendly VersionTakeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting
Oct 09, 2014Printer Friendly VersionFDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma
Sep 29, 2014Printer Friendly VersionSeattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Aug 08, 2014Printer Friendly VersionFDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma
Jun 19, 2014Printer Friendly VersionTakeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Jun 01, 2014Printer Friendly VersionVELCADE® (bortezomib)-based Therapy Significantly Improved Progression-Free Survival Compared to Standard Therapy as Frontline Treatment of Patients with Mantle Cell Lymphoma in Phase 3 Study
May 15, 2014Printer Friendly VersionOrteronel Plus Prednisone Improved Progression Free Survival in Men With Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase 3 Study